The steep R&D costs associated with antibiotics have largely driven away the industry in recent years, but PCAST also wants to fix that. To spur more development activity in the antibiotics arena, the advisory group is proposing economic incentives with particular attention to new classes of antibiotics.
Only a few major players--including Roche ($RHHBY), Cubist Pharmaceuticals ($CBST), Basilea ?Pharmaceutica ($BSLN) and Otsuka--are doing late-stage work in antibiotics right now.
"While there is a pressing need for new antibiotics, economic, regulatory and scientific circumstances make their development challenging for companies and have caused many to exit the space," Cubist Pharmaceuticals said in a statement in response to the executive order and PCAST report.
President Barack Obama's executive order also included a $20 million prize to drive the development of new diagnostic tests to identify highly resistant bacterial infections.
Antibiotics development is about to get a needed boost with the release of new federal proposals aimed at curbing rising antibacterial-resistant infections caused by so-called superbugs.
President Barack Obama
The recommendations, put forth by the President's Council of Advisors on Science and Technology (PCAST), include ways to speed drug development of new antibiotics and make clinical trials of these drugs more efficient in light of a dried-up global pipeline. Coinciding with an executive order signed yesterday, the proposals--if adopted--could help lure companies back to the challenging field.
One proposal that would affect small biotechs and Big Pharma alike is the creation of a "robust, standing national clinical trials network for antibiotic testing" that would be able to quickly enroll patients with dangerous bacterial infections. A benefit of such a network is that it would be able to test multiple new agents from different sponsors that could be evaluated simultaneously for their safety and efficacy.
The report, drafted by an outside panel of industry and academic experts, also pushes for approval of antimicrobial agents for use in limited patient populations so that people suffering from severe infections could benefit as quickly as possible from new drugs. The advisory group also wants to establish a Special Medical Use (SMU) pathway to help the FDA deliver such limited-use drugs to the market faster.
Wonder if the shill from Novartis gets paid to clutter a message board? Imitation is the best form of flattery. So we assume that Terry (and all his IDs) wishes he could be a normal investor that had a life, friends, and a family to enjoy. Pathetically sad!
What an effin Loser you are Terry!! I guess when you look in the mirror, you don't like what you see either! How sad is your existence.
That's another lie, Terry, which you are good at. All I ever have written regarding you is that you are a trader (probably in 10 lot increments, though). I could give a hoot about what you trade and at what price.
The other things I have said are that you are FOS with all the lies, distortions, and misrepresentations you post, and most of all that you are a Loser. I prefer to post facts, which you wouldn't know about.
It's about time the SEC nailed some of these hedge funds. The penalty should be more severe than just a fine. Some of the hedge fund partners (compliance personnel) should be restricted from any compensation for a year or two, and the guilty parties within the company ought not to be able to work in the industry at all.
You are probably right. Hopefully, it will be in the Sesame Street format, as he might be able to comprehend that.
You know, he's best friends with Bert & Ernie, but they don't know it yet because Terry has so many imaginary friends.
Terry, Since you know everything else, why don't you tell us what the FDA mandated to the company.
You ought to give the dog food to some canines, because they are man's best friend. I don't know what terry is to mankind. He only gives investment advice after the fact!
It's Terry Mooney. If you feel so discomfited? about this stock, and you believe hedge funds are manipulating it, and your wife is berating you for gambling, you don't have the gonads to be in this stock. Why don't you read Terry's investment newsletter on how to make money (he's up over 180% this past year). It's an unusual newsletter, but he is always right. He never forecasts what the future will be, he only tells you what he did in the past, after the results are in..
Sixth. The $64,000 question is, What is RIBT worth? This is a company that has a products that are probably produced inefficiently, that barely makes enough in revenues to pay the overhead, and has not had a profit for years, if at all.
There is probably not a commercial lender that would remotely consider this company and its management as a viable risk. Short needs to braid his ponytail, put on his Tommy Bahama shirt, and get back to sunglasses or underwear. He doesn't understand the food ingredient business or hands on management to turn around a company.
Based on their debts, warrants, diluted capital arrangements, revenue stream, and expenses, this company may not have a lot of value. So what is the "Right" price, and how is it justified?
Don't discount the possibility that Short and a selected few owners might consider taking it private. With all the dilution that has occurred, the legacy shareholders wouldn't put up much of a fight. It cost plenty to operate a small revenue company as a publicly traded entity. Why not go private, increase the revenue and fix the problems, and sell to someone else.